Bill

Bill > HB4293


OK HB4293

OK HB4293
Controlled dangerous substances; Veterans Mental Health Innovation Act; authorizing certain scientific research and clinical trials related to ibogaine; requiring registration; providing certain immunities; effective date.


summary

Introduced
02/02/2026
In Committee
02/10/2026
Crossed Over
Passed
Dead

Introduced Session

2026 Regular Session

Bill Summary

An Act relating to controlled dangerous substances; creating the Veterans Mental Health Innovation Act; authorizing certain entities to conduct scientific research and clinical trials related to ibogaine; specifying certain uses for which scientific research or clinical trials are authorized; limiting number of memoranda of agreement that universities or institutions of higher education may enter into; imposing requirements with respect to studies; requiring registration with the State Department of Health and the Oklahoma Department of Agriculture, Food, and Forestry; prescribing requirements for registration information; providing for specified nonrefundable fees; requiring additional registration with the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control; stipulating duration of registration; requiring certain notification of change of facility location; requiring written certifications for clinical trial participants; prescribing content of written certifications; providing for expiration of certifications; providing immunity to persons conducting or participating in research or clinical trials; requiring submission of written reports by certain date; providing for confidentiality of certain personal information; requiring specified agencies to maintain confidentiality with respect to information; directing promulgation of rules; providing for codification; and providing an effective date.

AI Summary

This bill, known as the Veterans Mental Health Innovation Act, authorizes certain entities in Oklahoma, such as universities or research facilities partnered with universities, to conduct scientific research and clinical trials on ibogaine, a substance derived from the Tabernanthe iboga plant, for the treatment of specific medical conditions in individuals aged 18 and older. These conditions include posttraumatic stress disorder, treatment-resistant depression and anxiety, traumatic brain injury, early-stage dementia, palliative and end-of-life care, opioid use disorder, and moderate to severe chronic pain. To conduct this research, eligible entities must register with the State Department of Health and the Oklahoma Department of Agriculture, Food, and Forestry, paying nonrefundable fees, and subsequently register annually with the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control. The bill outlines requirements for the research itself, including studying ibogaine's effectiveness and safety, reviewing existing literature, and examining its cultivation and processing. It also mandates written certifications for clinical trial participants, specifies the duration of registrations, and requires notification of any facility location changes. Importantly, the bill provides immunity from arrest, prosecution, or penalties for researchers and patients who comply with the provisions, and establishes an affirmative defense for individuals possessing ibogaine if they can demonstrate a qualifying medical condition. Researching entities are required to submit a comprehensive report on their findings by December 1, 2029, and all protected health information collected must be kept confidential and exempt from public records laws. The bill also directs relevant state agencies to create rules to implement this program and includes provisions for the future prescription and supervised administration of ibogaine by licensed physicians if it is approved by the U.S. Food and Drug Administration for medical treatment.

Committee Categories

Health and Social Services

Sponsors (1)

Last Action

Referred to Rules (on 02/10/2026)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...